141 related articles for article (PubMed ID: 37216403)
1. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
2. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
3. Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors.
Satish D; Lin IH; Flory J; Gerdes H; Postow MA; Faleck DM
Oncologist; 2023 Dec; 28(12):1085-1093. PubMed ID: 37285223
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis.
Shirwaikar Thomas A; Chari ST
Curr Gastroenterol Rep; 2023 Oct; 25(10):255-259. PubMed ID: 37845557
[TBL] [Abstract][Full Text] [Related]
5. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
Sayed Ahmed A; Abreo M; Thomas A; Chari ST
Curr Opin Gastroenterol; 2022 Sep; 38(5):516-520. PubMed ID: 35881977
[TBL] [Abstract][Full Text] [Related]
6. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
Nagao K; Sakai A; Tsumura H; Iemoto T; Hirata Y; Hori H; Ogisu K; Kakuyama S; Ikegawa T; Hirata T; Ezaki T; Furumatsu K; Yamanaka K; Kato T; Fujigaki S; Tanaka H; Yagi Y; Tanaka T; Kobayashi T; Masuda A; Shiomi H; Kodama Y
J Gastroenterol; 2024 May; 59(5):424-433. PubMed ID: 38421473
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors.
Hori Y; Naitoh I; Naiki-Ito A; Kawai T; Yoshida M; Kato A; Kachi K; Sahashi H; Adachi A; Toyohara T; Kito Y; Yamamoto T; Takahashi S; Kataoka H
Clin Transl Gastroenterol; 2024 Apr; 15(4):e00667. PubMed ID: 38088372
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic adverse events in patients treated with immune checkpoint inhibitors.
Hana C; Rehman T; Park K; Carracedo Uribe C; Aung PP; Hunis B; Salzberg M; Zikria J; Hussein A
JGH Open; 2023 Mar; 7(3):204-207. PubMed ID: 36968572
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.
Ashkar M; Chandra S; Vege SS; Takahashi H; Takahashi N; McWilliams RR
Cancer Immunol Immunother; 2023 Apr; 72(4):895-901. PubMed ID: 36161510
[TBL] [Abstract][Full Text] [Related]
11. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Hsu C; Marshall JL; He AR
Oncologist; 2020 Feb; 25(2):105-111. PubMed ID: 32043797
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature.
Tanabe K; Yokoyama K; Kanno A; Ikeda E; Ando K; Nagai H; Koyanagi T; Sakaguchi M; Nakaya T; Tamada K; Niki T; Fukushima N; Lefor AK; Yamamoto H
Intern Med; 2024 Mar; 63(6):791-798. PubMed ID: 37532549
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with IgG4-associated cholangitis.
Buechter M; Klein CG; Kloeters C; Schlaak JF; Canbay A; Gerken G; Kahraman A
Z Gastroenterol; 2014 Jun; 52(6):564-8. PubMed ID: 24905108
[TBL] [Abstract][Full Text] [Related]
14. Imaging findings of immune checkpoint inhibitor associated pancreatitis.
Das JP; Postow MA; Friedman CF; Do RK; Halpenny DF
Eur J Radiol; 2020 Oct; 131():109250. PubMed ID: 32905952
[TBL] [Abstract][Full Text] [Related]
15. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
17. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review.
Fang W; Gao Y; Shi X; Zhang X; Zhou S; Zhu H; Yan W; Wang H
Front Immunol; 2023; 14():1243773. PubMed ID: 37841238
[TBL] [Abstract][Full Text] [Related]
19. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study.
Kamisawa T; Yoshiike M; Egawa N; Nakajima H; Tsuruta K; Okamoto A
Pancreatology; 2005; 5(2-3):234-8; discussion 238-40. PubMed ID: 15855821
[TBL] [Abstract][Full Text] [Related]
20. Exocrine and endocrine pancreatic function in 21 patients suffering from autoimmune pancreatitis before and after steroid treatment.
Frulloni L; Scattolini C; Katsotourchi AM; Amodio A; Gabbrielli A; Zamboni G; Benini L; Vantini I
Pancreatology; 2010; 10(2-3):129-33. PubMed ID: 20460944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
